How Monjuvi Helps Treat Relapsed or Refractory DLBCL

Monjuvi offers a targeted antibody treatment option for certain adults with relapsed or refractory diffuse large B-cell lymphoma in combination with lenalidomide, providing an alternative when intensive chemotherapy is not suitable.

Monjuvi is a prescription antibody treatment for adults in the United States with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for intensive chemotherapy, used together with lenalidomide under an accelerated FDA approval granted in 2020 FDA, 07/31/2020.

As of: 06/08/2026 | Reading time: approx. 6 minutes

By the AD HOC NEWS editorial team - specialized in product-focused market coverage.

At a Glance

• Product: Monjuvi
• Category: CD19-directed monoclonal antibody for DLBCL
• Brand/Manufacturer: Incyte and MorphoSys
• Primary Use Cases: Treatment of relapsed or refractory DLBCL in adults not eligible for intensive chemotherapy
• Availability: Prescription-only medicine for eligible adults in the US
• Core Markets: United States and selected international markets

What Monjuvi Is and How It Works

Monjuvi is the brand name for tafasitamab-cxix, a laboratory-engineered monoclonal antibody that targets the CD19 protein on the surface of B cells involved in certain types of non-Hodgkin lymphoma such as diffuse large B-cell lymphoma.

By binding to CD19-positive cells, Monjuvi is designed to help the immune system recognize and attack malignant B cells, and it is given together with the oral cancer medicine lenalidomide in adults with relapsed or refractory DLBCL who cannot receive intensive chemotherapy Bristol Myers Squibb, 03/2024.

The product is administered by intravenous infusion on a repeating schedule that is outlined in the approved prescribing information, and treatment usually continues until disease progression or unacceptable toxicity, under the close supervision of a hematologist or oncologist.

Why Monjuvi Matters for US Consumers and Industry

For US adults facing relapsed or refractory DLBCL and unable to undergo intensive chemotherapy, Monjuvi in combination with lenalidomide offers a targeted option that can be used in outpatient oncology settings and may provide disease control when other therapies are not suitable FDA, 07/31/2020.

This use is based on clinical data that showed antitumor activity in adults with relapsed or refractory DLBCL treated with tafasitamab plus lenalidomide, leading regulators to grant accelerated approval, which links ongoing availability to confirmation of benefit in further studies FDA, 07/2020.

Because DLBCL is one of the most common aggressive non-Hodgkin lymphomas in the United States, a treatment like Monjuvi that can be offered to patients ineligible for more intensive regimens has become a relevant option in the care landscape and part of specialized discussions in US cancer centers.

Monjuvi in the US and Global Market

In the US, Monjuvi is commercialized by Incyte and is available by prescription in specialty oncology practices and hospitals, with use guided by the FDA-approved indication and accompanied by safety monitoring requirements that reflect the risks of serious infections, blood count changes, and infusion-related reactions Incyte, 2024.

Outside the United States, the medicine is also marketed under the name Minjuvi in some regions, reflecting the international collaboration between MorphoSys and Incyte, and US hematologists may see patients who started similar CD19-directed antibody therapy abroad when assessing prior treatment history MorphoSys, 2024.

Across the global lymphoma treatment landscape, CD19-directed antibodies like tafasitamab are part of a broader trend toward targeted immunotherapies, including CAR-T cell treatments and other monoclonal antibodies, which have become increasingly important in the care of relapsed or refractory B-cell lymphomas and are frequently discussed at major hematology meetings.

• CD19-targeted antibody-infused therapy option
• Used with lenalidomide in adults with relapsed or refractory DLBCL
• Intended for patients not eligible for intensive chemotherapy
• Available in US oncology practices and hospitals by prescription
• Requires monitoring for infections and blood count changes

Frequently Asked Questions About Monjuvi

Who can receive Monjuvi treatment in the US?
Monjuvi is indicated for adults with relapsed or refractory diffuse large B-cell lymphoma who are not candidates for intensive chemotherapy and who receive it in combination with lenalidomide under the supervision of an oncology specialist Incyte, 2024.

How is Monjuvi given to patients?
The medicine is administered as an intravenous infusion according to a dosing schedule described in the prescribing information, with premedication and monitoring as recommended by the treatment team to help reduce the risk of infusion-related reactions.

What are key safety considerations with Monjuvi?
Important safety considerations include the risk of serious infections, low blood cell counts, and infusion-related reactions, and clinicians typically follow guidance in the prescribing information regarding monitoring and dose adjustments for adult patients receiving this combination therapy.

The company behind Monjuvi is MorphoSys, a biopharmaceutical developer that has focused on antibody-based therapies in oncology and partnered with Incyte for commercialization in key markets.

Shares in the issuer associated with Monjuvi are identified under the ISIN DE0006632003, and the stock is part of the broader biotechnology segment that attracts attention from investors following advances in targeted cancer therapies.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.